{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:57:18Z","timestamp":1785855438592,"version":"3.56.0"},"reference-count":73,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"Importance<\/jats:title>Cannabinoids are increasingly used for medical purposes in children. Evidence of the safety of cannabinoids in this context is sparse, creating a need for reliable information to close this knowledge gap.<\/jats:p><\/jats:sec>Objective<\/jats:title>To study the adverse event profile of cannabinoids used for medical purposes in children and adolescents.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>For this systematic review and meta-analysis, MEDLINE, Embase, PsycINFO, and the Cochrane Library were searched for randomized clinical trials published from database inception to March 1, 2024, for subject terms and keywords focused on cannabis and children and adolescents. Search results were restricted to human studies in French or English.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Two reviewers independently performed the title, abstract, and full-text review, data extraction, and quality assessment. Included studies enrolled at least 1 individual 18 years or younger, had a natural or pharmaceutical cannabinoid used as an intervention to manage any medical condition, and had an active comparator or placebo.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Two reviewers performed data extraction and quality assessment independently. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline and PRISMA-S guideline were used. Data were pooled using a random-effects model.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the incidence of withdrawals, withdrawals due to adverse events, overall adverse events, and serious adverse events in the cannabinoid and control arms. Secondary outcomes were the incidence of specific serious adverse events and adverse events based on organ system involvement.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 39\u202f175 citations, 23 RCTs with 3612 participants were included (635 [17.6%] female and 2071 [57.3%] male; data not available from 2 trials); 11 trials (47.8%) included children and adolescents only, and the other 12 trials (52.2%) included children, adolescents, and adults. Interventions included purified cannabidiol (11 [47.8%]), nabilone (4 [17.4%]), tetrahydrocannabinol (3 [13.0%]), cannabis herbal extract (3 [13.0%]), and dexanabinol (2 [8.7%]). The most common indications were epilepsy (9 [39.1%]) and chemotherapy-induced nausea and vomiting (7 [30.4%]). Compared with the control, cannabinoids were associated with an overall increased risk of adverse events (risk ratio [RR], 1.09; 95% CI, 1.02-1.16; I<\/jats:italic>2<\/jats:sup>\u2009=\u200954%; 12 trials), withdrawals due to adverse events (RR, 3.07; 95% CI, 1.73-5.43; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%; 14 trials), and serious adverse events (RR, 1.81; 95% CI, 1.21-2.71; I<\/jats:italic>2<\/jats:sup>\u2009=\u200959%; 11 trials). Cannabinoid-associated adverse events with higher RRs were diarrhea (RR, 1.82; 95% CI, 1.30-2.54; I<\/jats:italic>2<\/jats:sup>\u2009=\u200935%; 10 trials), increased serum levels of aspartate aminotransferase (RR, 5.69; 95% CI, 1.74-18.64; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%; 5 trials) and alanine aminotransferase (RR, 5.67; 95% CI, 2.23-14.39; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%; 6 trials), and somnolence (RR, 2.28; 95% CI, 1.83-2.85; I<\/jats:italic>2<\/jats:sup>\u2009=\u20098%; 14 trials).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this systematic review and meta-analysis, cannabinoids used for medical purposes in children and adolescents in RCTs were associated with an increased risk of adverse events. The findings suggest that long-term safety studies, including those exploring cannabinoid-related drug interactions and tools that improve adverse event reporting, are needed.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2024.3045","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:06:40Z","timestamp":1726499200000},"page":"1124","source":"Crossref","is-referenced-by-count":17,"title":["Cannabinoids Used for Medical Purposes in Children and Adolescents"],"prefix":"10.1001","volume":"178","author":[{"given":"Manik","family":"Chhabra","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ben-Eltriki","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Mansell","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00ea-Linh","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"Neil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Huntsman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Children\u2019s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"poi240055r1","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting.","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P T"},{"issue":"24","key":"poi240055r2","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis.","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"poi240055r3","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/j.pain.0000000000001929","article-title":"Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.","volume":"162","author":"Fisher","year":"2021","journal-title":"Pain"},{"issue":"1","key":"poi240055r4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42238-022-00142-z","article-title":"Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario.","volume":"4","author":"de Souza","year":"2022","journal-title":"J Cannabis Res"},{"issue":"5","key":"poi240055r5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1818","article-title":"Medical cannabinoids in children and adolescents: a systematic review.","volume":"140","author":"Wong","year":"2017","journal-title":"Pediatrics"},{"issue":"1","key":"poi240055r6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12152-022-09478-y","article-title":"Neither the \u201cdevil\u2019s lettuce\u201d nor a \u201cmiracle cure:\u201d the use of medical cannabis in the care of children and youth.","volume":"15","author":"Gunning","year":"2022","journal-title":"Neuroethics"},{"issue":"3-4","key":"poi240055r7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000521683","article-title":"Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals.","volume":"107","author":"Legare","year":"2022","journal-title":"Pharmacology"},{"key":"poi240055r8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-21737-2","article-title":"Pharmacology of medical cannabis.","volume":"1162","author":"Amin","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"poi240055r9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","article-title":"Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.","volume":"239","author":"Leung","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"22","key":"poi240055r10","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1002\/cncr.34920","article-title":"Cannabinoids for symptom management in children with cancer: a systematic review and meta-analysis.","volume":"129","author":"Chhabra","year":"2023","journal-title":"Cancer"},{"issue":"17","key":"poi240055r13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis.","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"poi240055r14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.14608","article-title":"Cannabis-based products for pediatric epilepsy: a systematic review.","volume":"60","author":"Elliott","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"poi240055r15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","article-title":"A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).","volume":"14","author":"Berry-Kravis","year":"2022","journal-title":"J Neurodev Disord"},{"issue":"1","key":"poi240055r16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial.","volume":"12","author":"Aran","year":"2021","journal-title":"Mol Autism"},{"key":"poi240055r17","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.","volume":"46","author":"Silva","year":"2024","journal-title":"Trends Psychiatry Psychother"},{"issue":"8","key":"poi240055r18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28442","article-title":"Cannabidiol in treatment of autism spectrum disorder: a case study.","volume":"14","author":"Ma","year":"2022","journal-title":"Cureus"},{"key":"poi240055r19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.979403","article-title":"Terpene-enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: case report.","volume":"13","author":"Raz","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"poi240055r20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/dmcn.14548","article-title":"Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.","volume":"62","author":"Fairhurst","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"poi240055r21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(05)70253-2","article-title":"Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.","volume":"5","author":"Maas","year":"2006","journal-title":"Lancet Neurol"},{"issue":"41","key":"poi240055r22","doi-asserted-by":"publisher","first-page":"E1596","DOI":"10.1503\/cmaj.202169","article-title":"Improving the regulation of medical cannabis in Canada to better serve pediatric patients.","volume":"193","author":"Huntsman","year":"2021","journal-title":"CMAJ"},{"issue":"1","key":"poi240055r23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence.","volume":"16","author":"Arnold","year":"2023","journal-title":"Clin Transl Sci"},{"key":"poi240055r24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2023.07.029","article-title":"Cannabidiol\u2019s impact on drug-metabolization.","volume":"118","author":"St\u00f6llberger","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"3","key":"poi240055r25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants.","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"poi240055r26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/can.2022.0192","article-title":"Therapeutic effects of medicinal cannabinoids on the gastrointestinal system in pediatric patients: a systematic review.","volume":"7","author":"Sunil","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"poi240055r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis.","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"poi240055r28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement.","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"poi240055r29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews.","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"issue":"6","key":"poi240055r30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1440-1797.2010.01380.x","article-title":"How to write a Cochrane systematic review.","volume":"15","author":"Henderson","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"poi240055r32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement.","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"poi240055r33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5596\/c14-016","article-title":"Product review: Covidence (systematic review software).","volume":"35","author":"Babineau","year":"2014","journal-title":"J Can Health Libr Assoc"},{"key":"poi240055r34","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"poi240055r35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1177\/0962280215583568","article-title":"Random-effects meta-analysis: the number of studies matters.","volume":"26","author":"Guolo","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"poi240055r36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40537-023-00823-3","article-title":"Cochran\u2019s Q test for analyzing categorical data under uncertainty.","volume":"10","author":"Aslam","year":"2023","journal-title":"J Big Data"},{"issue":"3","key":"poi240055r37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/anae.13355","article-title":"Funnels for publication bias\u2014have we lost the plot?","volume":"71","author":"Choi","year":"2016","journal-title":"Anaesthesia"},{"issue":"2","key":"poi240055r38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bcp.14399","article-title":"A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability.","volume":"87","author":"Efron","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"poi240055r39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial.","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"issue":"12","key":"poi240055r40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","article-title":"Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.","volume":"2","author":"Ekert","year":"1979","journal-title":"Med J Aust"},{"issue":"6","key":"poi240055r41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","article-title":"Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation.","volume":"91","author":"Chang","year":"1979","journal-title":"Ann Intern Med"},{"issue":"14","key":"poi240055r42","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"23","key":"poi240055r43","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","article-title":"Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.","volume":"300","author":"Herman","year":"1979","journal-title":"N Engl J Med"},{"issue":"S1","key":"poi240055r44","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","article-title":"Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.","volume":"21","author":"Einhorn","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"21","key":"poi240055r45","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"poi240055r46","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome.","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"poi240055r47","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/adc.61.5.502","article-title":"Nabilone: an alternative antiemetic for cancer chemotherapy.","volume":"61","author":"Dalzell","year":"1986","journal-title":"Arch Dis Child"},{"issue":"10125","key":"poi240055r48","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"poi240055r49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","article-title":"A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy.","volume":"34","author":"Ben-Menachem","year":"2020","journal-title":"CNS Drugs"},{"issue":"10","key":"poi240055r50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"poi240055r51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial.","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"9","key":"poi240055r52","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/epi.16974","article-title":"Time to onset of cannabidiol treatment effects in Dravet syndrome: analysis from two randomized controlled trials.","volume":"62","author":"Madan Cohen","year":"2021","journal-title":"Epilepsia"},{"issue":"6","key":"poi240055r53","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"issue":"3","key":"poi240055r54","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00003246-200203000-00009","article-title":"Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.","volume":"30","author":"Knoller","year":"2002","journal-title":"Crit Care Med"},{"issue":"3","key":"poi240055r55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJM198001173020302","article-title":"Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.","volume":"302","author":"Sallan","year":"1980","journal-title":"N Engl J Med"},{"issue":"6","key":"poi240055r56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials.","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"poi240055r57","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"issue":"12","key":"poi240055r58","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1080\/17512433.2022.2142114","article-title":"Cannabidiol drug interaction considerations for prescribers and pharmacists.","volume":"15","author":"Graham","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"poi240055r60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/v13061099","article-title":"The link between cannabis use, immune system, and viral infections.","volume":"13","author":"Maggirwar","year":"2021","journal-title":"Viruses"},{"issue":"10","key":"poi240055r61","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1523\/JNEUROSCI.3375-17.2018","article-title":"Grey matter volume differences associated with extremely low levels of cannabis use in adolescence.","volume":"39","author":"Orr","year":"2019","journal-title":"J Neurosci"},{"key":"poi240055r62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fpsyt.2013.00053","article-title":"Dare to delay? the impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function.","volume":"4","author":"Lisdahl","year":"2013","journal-title":"Front Psychiatry"},{"issue":"1","key":"poi240055r63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ajog.2016.07.010","article-title":"Medical marijuana laws and pregnancy: implications for public health policy.","volume":"216","author":"Chasnoff","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"poi240055r64","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.biopsych.2015.09.009","article-title":"At the tip of an iceberg: prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring.","volume":"79","author":"Alp\u00e1r","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"2","key":"poi240055r65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jama.2016.18612","article-title":"The risks of marijuana use during pregnancy.","volume":"317","author":"Volkow","year":"2017","journal-title":"JAMA"},{"key":"poi240055r66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain.","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"issue":"23","key":"poi240055r67","doi-asserted-by":"publisher","first-page":"9800","DOI":"10.1073\/pnas.0703472104","article-title":"[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.","volume":"104","author":"Burns","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"poi240055r68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.biopsych.2006.02.014","article-title":"Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users.","volume":"61","author":"Jacobsen","year":"2007","journal-title":"Biol Psychiatry"},{"key":"poi240055r69","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1196\/annals.1308.053","article-title":"Impact of cannabis use on brain function in adolescents.","volume":"1021","author":"Jacobsen","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"poi240055r70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.addbeh.2016.05.015","article-title":"Comparing adults who use cannabis medically with those who use recreationally: results from a national sample.","volume":"61","author":"Lin","year":"2016","journal-title":"Addict Behav"},{"issue":"2","key":"poi240055r71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/pch\/pxad078","article-title":"Medical cannabis for children: evidence and recommendations.","volume":"29","author":"Kelly","year":"2024","journal-title":"Paediatr Child Health"},{"issue":"1","key":"poi240055r72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/00952990.2017.1306746","article-title":"Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults.","volume":"44","author":"Nader","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"9","key":"poi240055r73","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/npp.2014.67","article-title":"Long-term effects of cannabis on brain structure.","volume":"39","author":"Battistella","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"poi240055r11","unstructured":"Prepidiolex (cannabidiol). Package insert. GW Research Ltd; 2023. Accessed May 23, 2024. https:\/\/pp.jazzpharma.com\/pi\/epidiolex.ca.PM-en.pdf?"},{"key":"poi240055r12","unstructured":"Epidiolex (cannabidiol) oral solution. Package insert. Jazz Pharmaceuticals; 2024. Accessed May 23, 2024. https:\/\/pp.jazzpharma.com\/pi\/epidiolex.en.USPI.pdf"},{"key":"poi240055r31","unstructured":"Search strategy for cannabinoids used for medical purposes in children: a living systematic review. Accessed March 8, 2024. https:\/\/borealisdata.ca\/dataset.xhtml?persistentId=doi:10.34990\/FK2\/MV6CMP"},{"key":"poi240055r59","doi-asserted-by":"crossref","unstructured":"Gaston? TE, Bebin? EM, Cutter? GR, . Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy Behav. 2019;98(pt A):201-206.","DOI":"10.1016\/j.yebeh.2019.07.008"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2823468\/jamapediatrics_chhabra_2024_oi_240055_1730472677.70264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:01:44Z","timestamp":1730736104000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2823468"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2024.3045","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}